Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in ChinaOA
This study sought to conduct an evaluation of the cost‑effectiveness of toripalimab plus bevacizumab versus sorafenib in the treatment of patients with advanced hepatocellular carcinoma(HCC)in the context of the Chinese healthcare system.Based on the clinical trial(Trial No.:NCT04723004),we developed a partitioned survival model to simulate patients’lifetime health outcomes and economic costs.The analysis assessed economic value by analyzing incremental cost‑effectiveness ratio(ICER)and quality‑adjusted life years(QALYs).We assessed the model’s reliability using both one‑way sensitivity analysis and probabilistic sensitivity analysis.The base case analysis indicated that toripalimab plus bevacizumab had an incremental cost of$52,351.47 and an incremental QALY of 0.24,resulting in an ICER of$220,179.20 per QALY gained.This exceeds China’s willingness‑to‑pay(WTP)threshold of$38,224 per QALY.Sensitivity analysis confirmed the robustness of the model results.The cost‑effectiveness analysis results indicated that the combination of toripalimab and bevacizumab is not cost‑effective for patients with advanced HCC in China.
Yize Jia;Shuo Yang;Shan Zhao;Shuo Kang
School of Pharmacy,Hebei Medical University,Shijiazhuang 050017,ChinaSchool of Pharmacy,Hebei Medical University,Shijiazhuang 050017,ChinaDepartment of Oncology,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,ChinaMedical Insurance Office,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,China
医药卫生
ToripalimabBevacizumabSorafenibHepatocellular carcinomaPartitioned survival modelCost‑effectiveness analysis
《Pharmacoeconomics and Policy》 2026 (1)
P.19-26,8
评论